Spire Healthcare Group (LON:SPI) Trading Down 22.1% Following Analyst Downgrade

Spire Healthcare Group plc (LON:SPI) shares were down 22.1% during mid-day trading on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 174.60 ($2.26) and last traded at GBX 174.80 ($2.26). Approximately 1,500,525 shares changed hands during mid-day trading, an increase of 157% from the average daily volume of 584,388 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Price Performance

The company has a debt-to-equity ratio of 62.25, a quick ratio of 0.74 and a current ratio of 0.70. The company’s fifty day simple moving average is GBX 227.28 and its two-hundred day simple moving average is GBX 229.74. The stock has a market capitalization of £711.58 million, a PE ratio of 25.22, a P/E/G ratio of 1.06 and a beta of 0.96.

Spire Healthcare Group (LON:SPI) last posted its earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) earnings per share for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. As a group, sell-side analysts predict that Spire Healthcare Group plc will post 15.6634747 EPS for the current year.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.